Cabozantinib in Hepatocellular Carcinoma
type: MedicalStudy
description: A Phase II Clinical Trial to Study the Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma Refractory to Checkpoint Inhibitors
status: ACTIVE_NOT_RECRUITING
study design: INTERVENTIONAL
phase: PHASE2
start date: 2020-11-01
end date: 2028-12-31
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT04588051
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Stephen Chan Lam
study subject: HCC
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: ACTIVE_NOT_RECRUITING
keywords: HCC

AI Analytics
type: Organization